US FDA approves Cipla's Lanreotide injection for acromegaly and GEP-NETs, strengthening its US market position.
Indian pharmaceutical firm Cipla has received final approval from the US FDA for its Lanreotide injection, which treats acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval strengthens Cipla's position in the US market and aligns with its growth strategy in the complex product segment. Lanreotide injection is a generic version of Somatuline Depot injection, with US sales of approximately $898M in the last year.
May 22, 2024
7 Articles